Last reviewed · How we verify
NCT05618626: MAUCO+
Prevention of NAFLD and CVD Through Lifestyle Intervention
NA trial testing Physical exercise and dietary intervention for NAFLD in Non-Alcoholic Fatty Liver Disease in 300 participants. Currently enrolling.
28 April 2025
Quick facts
| Lead sponsor | Pontificia Universidad Catolica de Chile |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 27 September 2021 |
| Primary completion | 28 April 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across Chile |
Drugs / interventions tested
- Physical exercise and dietary intervention for NAFLD
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
- Gallstone Disease — all drugs for Gallstone Disease →
Sponsor
Pontificia Universidad Catolica de Chile — full company profile →
Who can join
Adults 45 to 60, any sex, with Non-Alcoholic Fatty Liver Disease or Gallstone Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid profile, insulin resistance, cardiovascular risk, NAFLD, and maintain a healthier lifestyle. Through the implementation of physical activity and nutritional programs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Developing a non-invasive algorithm for the diagnosis of steatotic liver disease in primary healthcare: a retrospective cohort study.
Spencer-Sandino M, Godoy F, Alvares D, Elorrieta F, et al · · 2025 · PMID 41386970 · DOI 10.1136/bmjhci-2025-101620
Verify or expand the search:
- PubMed search for NCT05618626
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other Pontificia Universidad Catolica de Chile trials
Trials by the same sponsor.
- NCT07396129 — Assessing the Efficacy of a High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Pain · Phase 1, PHASE2 · not yet recruiting
- NCT07510425 — Artificial Intelligence vs. Automated Messaging for Continuous Regional Analgesia Follow-up · NA · not yet recruiting
- NCT07380451 — Modular Intervention for Depression Study · NA · not yet recruiting
- NCT07324499 — Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Bl · NA · not yet recruiting
- NCT07330947 — Incidence and Risk Factors of Postoperative Chronic Pain in Patients Who Have Undergone Hallux Valgus Surgery · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05618626 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pontificia Universidad Catolica de Chile
- Last refreshed: 19 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05618626.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing